載入中
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
前收盤價
US$77.87
−US$1.13 · -1.43%
盤前
US$78.63
+US$0.76 · +0.98%
10月12日 上午7:00 ET
盤中時間採用ET。市場資料可能有所延遲。
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
日內區間
目前US$77.87
52週區間
目前US$77.87
盤中時間採用ET。市場資料可能有所延遲。
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
日內區間
目前US$77.87
52週區間
目前US$77.87
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.05億 USD | 4.42億 USD | 2.42億 USD | 9345.9萬 USD | 3026.2萬 USD |
| 銷貨成本 | 2.43億 USD | 1.79億 USD | 8753萬 USD | 2818.7萬 USD | 910.3萬 USD |
| 毛利 | 3.63億 USD | 2.62億 USD | 1.54億 USD | 6527.2萬 USD | 2115.9萬 USD |
| 研究與開發 | 6905.5萬 USD | 5596.8萬 USD | 6326.7萬 USD | 2681.2萬 USD | 2230.4萬 USD |
| 銷售、一般及管理費用 | 1.85億 USD | 1.69億 USD | 1.2億 USD | 6989.7萬 USD | 3828.3萬 USD |
| 營業費用 | 2.54億 USD | 2.25億 USD | 1.83億 USD | 9670.9萬 USD | 6058.7萬 USD |
| 利息收入 | — | — | 1250萬 USD | 90萬 USD | — |
| 利息支出 | 1378.2萬 USD | 1440.9萬 USD | 1079.1萬 USD | 372.6萬 USD | 387.4萬 USD |
| 折舊和攤銷 | 2718.5萬 USD | 1975.8萬 USD | 817.7萬 USD | 347.8萬 USD | 181.7萬 USD |
| 營業利益 | 1.09億 USD | 3749.6萬 USD | −2872.7萬 USD | −3143.7萬 USD | −3942.8萬 USD |
| 淨利 | 1.9億 USD | 3546.4萬 USD | −2502.8萬 USD | −3623.1萬 USD | −4421.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$99.75
上漲空間 28.10%報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.64億0.16%1031.91億 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI8839.14萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM7108.97萬0.09%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB6406.5萬0.03%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK3670.16萬0.08%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF3410.28萬0.04%954億 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2525.39萬0.16%158.4億 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO2504.85萬0.18%139.17億 USD0.24%US$356.78+0.94%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
